Circulating angiopoietin-like protein 8 (betatrophin) association with HsCRP and metabolic syndrome

Abu‐Farha, Mohamed; Abubaker, Jehad; Al-Khairi, Irina; Cherian, Preethi; Noronha, Fiona; Kavalakatt, Sina; Khadir, Abdelkrim; Behbehani, Kazem; Alarouj, Monira; Bennakhi, Abdullah; Elkum, Naser

doi:10.1186/s12933-016-0346-0

Cited by 74 publications

(81 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The varying results observed in the reported ANGPTL8 levels may also be in part due to other comorbidities that can play a role in regulating the ANGPTL8 levels. For example, it has been reported that ANGPTL8 level may be affected by thyroid function, polycystic ovary syndrome as well as metabolic syndrome (MetS) . We have also recently shown that ANGPTL8 was higher in people with MetS than those without.…”

Section: Angptl8 Role In Obesitymentioning

confidence: 82%

“…For example, it has been reported that ANGPTL8 level may be affected by thyroid function, 43 polycystic ovary syndrome 44 as well as metabolic syndrome (MetS). 45,46 We have also recently shown that ANGPTL8 was higher in people with MetS than those without. When stratified according to the number of MetS components, people with higher number of MetS components had significantly higher level of ANGPTL8.…”

Section: Angptl8 Role In Obesitymentioning

confidence: 89%

“…When stratified according to the number of MetS components, people with higher number of MetS components had significantly higher level of ANGPTL8. 47 Similarly, Crujeiras et al have recently shown that ANGPTL8 was increased in obese people with MetS, and it was associated with less reduction in adiposity and dyslipidemia after a weight-loss program. 45…”

Section: Angptl8 Role In Obesitymentioning

confidence: 94%

See 2 more Smart Citations

ANGPTL8 (betatrophin) role in diabetes and metabolic diseases

Abu‐Farha

Abubaker

Tuomilehto

2017

Diabetes Metabolism Res

Self Cite

View full text Add to dashboard Cite

Diabetes is a major disease worldwide that is reaching epidemic levels. Its increased prevalence as well as its association with a high number of complications such as cardiovascular diseases, nephropathy, and retinopathy makes it an important disease for investigation. ANGPTL8 is a recently identified hormone that has been associated with two functionally important processes in the development of type 2 diabetes, insulin resistance as well as lipid metabolism. Initial work has shown that ANGPTL8 was expressed in liver, white adipose, and brown adipose tissues. ANGPTL8 regulates the activity of lipoprotein lipase, which is a key enzyme in lipoprotein lipolysis pathway through its direct interaction with ANGPTL3. It has been also reported that it regulates the replication of β-cells in response to insulin resistance. As a result, many recent studies have focused on the association of ANGPTL8 with diabetes and obesity as well as its association with various metabolic markers in order to better understand its physiological role in glucose homeostasis and lipid metabolism. In this review, we will highlight some of the key clinical findings, mainly from human studies, that investigated the role of ANGPTL8 in metabolic diseases such as diabetes, obesity, and the metabolic syndrome.

show abstract

Section: Angptl8 Role In Obesitymentioning

confidence: 82%

Section: Angptl8 Role In Obesitymentioning

confidence: 89%

Section: Angptl8 Role In Obesitymentioning

confidence: 94%

See 1 more Smart Citation

ANGPTL8 (betatrophin) role in diabetes and metabolic diseases

Abu‐Farha

Abubaker

Tuomilehto

2017

Diabetes Metabolism Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…Betatrophin has recently emerged as an indicator of metabolic disorders, with two separate case-control studies finding that betatrophin levels are elevated in subjects with metabolic syndrome and hypertension [31,32]. A Chinese study of non-diabetic individuals found that circulating full-length betatrophin levels are an independent risk factor for coronary artery disease (CAD) and are positively associated with its severity [33].…”

Section: Discussionmentioning

confidence: 99%

Circulating betatrophin/ANGPTL8 levels correlate with body fat distribution in individuals with normal glucose tolerance but not those with glucose disorders

et al. 2020

View full text Add to dashboard Cite

Background: The relationship between betatrophin/ANGPTL8 and obesity has been investigated using body mass index (BMI); however, since BMI reflects overall adiposity rather than body fat distribution, it remains unclear whether fat deposition in different areas of the body affects betatrophin expression. Here, we investigated the correlation between circulating betatrophin levels and body fat distribution in patients with different glucose tolerance. Methods: We performed a cross-sectional study in 128 participants with impaired glucose tolerance (IGT; n = 64) or normal glucose tolerance (NGT; n = 64). Circulating betatrophin levels were detected by enzyme-linked immunosorbent assay (ELISA). Body fat distribution (subcutaneous, visceral, and limb fat) was measured by magnetic resonance imaging (MRI) and a body fat meter.Results: After controlling for age, sex, and BMI, betatrophin was correlated positively with visceral adipose tissue-tosubcutaneous adipose tissue ratio (VAT/SAT ratio; r = 0.339, p = 0.009) and negatively with body fat ratio (BFR; r = − 0.275, p = 0.035), left lower limb fat ratio (LLR; r = − 0.330, p = 0.011), and right lower limb fat ratio (RLR; r = − 0.288, p = 0.027) in the NGT group, with these correlations remaining after controlling for triglycerides. VAT/SAT ratio (standardized β = 0.419, p = 0.001) was independently associated with serum betatrophin levels; however, betatrophin was not associated with body fat distribution variables in the IGT group.Conclusions: Circulating betatrophin levels correlated positively with VAT/SAT ratio and negatively with lower limb fat, but not with subcutaneous or upper limb fat, in individuals with normal glucose tolerance. Thus, betatrophin may be a potential biomarker for body fat distribution in individuals without glucose disorders.

show abstract

“…However, the mechanism underlying these links is unclear, partly because of the lack of appropriate animal models and the difficulty related human studies. Recently, a large number of adipokines and cytokines have been reported to be related to insulin resistance and MetS, such as betatrophin, zinc-α2-glycoprotein (ZAG) and myonectin [3][4][5][6]. Therefore, investigation of the relationship between new cytokines and MetS has an important clinical significance.…”

Section: Introductionmentioning

confidence: 99%

High Circulating Alarin Levels Are Associated with Presence of Metabolic Syndrome

Xia

Zhang

Yang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Alarin has been reported to be related with increased food intake and body weight. The relationship of circulating Alarin with insulin resistance or metabolic syndrome (MetS), however, is unknown. This study aimed to investigate the physiological role of Alarin and its association with MetS in humans. Methods: Newly diagnosed MetS patients (n=237) and age-matched healthy subjects (n=192) were recruited for this study. Oral glucose tolerance test, treadmill exercise, lipid infusions and euglycemic-hyperinsulinemic clamp (EHCs) were performed. Circulating Alarin and TNFα levels were measured by ELISA. Results: Circulating Alarin levels were significantly higher in MetS patients compared with healthy subjects (0.46 ± 0.22 vs. 0.41 ± 0.14 µg/L, P < 0.01). In all studied subjects, circulating Alarin levels were positively correlated with WC, blood pressure, FBG, triglyceride, HbA1c, HOMA-IR, AUC_glucose, and TNFα (P < 0.05 or P < 0.01). Multivariate logistic regression analyses revealed that circulating Alarin levels were correlated with MetS and insulin resistance. There was no significant change of circulating Alarin levels in the subjects with treadmill exercise for 45 min. In healthy individuals, however, glucose challenge, acute hyperglycemia and lipid infusions resulted in increased circulating Alarin levels, while acute hyperinsulinaemia transiently decreased circulating Alarin levels. Conclusion: The present study provides the evidence that circulating Alarin levels are associated with MetS and insulin resistance.

show abstract

Circulating angiopoietin-like protein 8 (betatrophin) association with HsCRP and metabolic syndrome

Cited by 74 publications

References 43 publications

ANGPTL8 (betatrophin) role in diabetes and metabolic diseases

ANGPTL8 (betatrophin) role in diabetes and metabolic diseases

Circulating betatrophin/ANGPTL8 levels correlate with body fat distribution in individuals with normal glucose tolerance but not those with glucose disorders

High Circulating Alarin Levels Are Associated with Presence of Metabolic Syndrome

Contact Info

Product

Resources

About